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Introduction
The feasibility of antibody-based immunotherapy in humans
by means of targeted delivery of therapeutics may require
specific human or humanized internalizing antibodies. Large
non-immune phage antibody libraries have been developed to
serve as a single source for the rapid generation of fully human
antibodies (Marks et al., 1991; Nissim et al., 1994; Vaughan et
al., 1996; Pini et al., 1998). In the search for internalizing
antibodies, Poul and co-workers devised a selection strategy
that took advantage of both normal cell surface receptor
biology and phage antibody mimicry capacity. They
demonstrated that specific phages endocytosed upon binding
could be successfully recovered from the cell cytosol after
stringent removal of non-specific phage from the cell surface
(Poul et al., 2000). In this study we report the successful
application of their strategy to select a single-chain antibody
fragment (scFv) internalizing into human tumor cells from a
fully human scFv library displayed monovalently on phage
(Viti et al., 2000). This scFv is specific for the activated
leukocyte cell adhesion molecule (ALCAM/CD166).
ALCAM/CD166 is a member of the immunoglobulin gene
superfamily belonging to a subgroup with five extracellular
immunoglobulin-like domains (VVC2C2C2), which includes
MCAM/CD146/MUC18 and B-CAM/Lutheran. These
molecules are involved in the development and maintenance of
tissue architecture, neurogenesis, hematopoiesis, immune
responses and tumor progression. ALCAM/CD166 mediates
cell-cell clustering through homophilic (ALCAM-ALCAM)
and heterophilic (ALCAM-CD6) interactions. Its pattern of
expression in human tissues and cells is broad and includes
epithelia, neurons, lymphoid and myeloid cells, hematopoietic
and mesenchymal stem cells (reviewed by Swart, 2002). The
relevance of the engagement of the heterophilic pair CD166-
CD6 for optimal activation of T cells has been recently
demonstrated (Hassan et al., 2004). Moreover, developmental
biology studies showed that ALCAM/CD166 expression
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(ALCAM/CD166), a member of the immunoglobulin
superfamily with five extracellular immunoglobulin-like
domains, promotes heterophilic (ALCAM-CD6) and
homophilic (ALCAM-ALCAM) cell-cell interactions. Here
we describe a fully human single-chain antibody fragment
(scFv) directed to ALCAM/CD166. We selected the I/F8
scFv from a phage display library of human V-gene
segments by cell panning and phage internalization into
IGROV-I human ovary carcinoma cells. The I/F8 specificity
was identified as ALCAM/CD166 by matrix-assisted laser
desorption/ionisation time-of-flight (MALDI-TOF) peptide
mass fingerprinting of the I/F8-immunoprecipitated
protein. The I/F8 scFv reacts with the human, monkey and
murine ALCAM/CD166 molecule, indicating that the
recognized epitope is highly conserved. The I/F8 scFv
completely abolished binding of both ALCAM/Fc and
CD6/Fc soluble ligands, whereas it did not compete with
the anti-ALCAM/CD166 murine monoclonal antibodies
J4-81 and 3A6 and therefore recognizes a different epitope.
Engagement through I/F8 scFv, 3A6 monoclonal antibody
or CD6/Fc ligand induced ALCAM/CD166 internalization,
with a kinetics slower than that of transferrin in the same
cells. Newly internalized I/F8-ALCAM complexes
colocalized with clathrin but not with caveolin and we
demonstrated, using surface biotinylation and recycling
assays, that endocytosed ALCAM/CD166 recycles back to
the cell surface. Such an endocytic pathway allows the
efficient delivery of an I/F8 scFv-saporin immunotoxin into
tumor cells, as the conjugates are able to selectively kill cell
lines expressing ALCAM/CD166. Altogether these data
provide evidence of the suitability of the I/F8 scFv for
further functional analysis of ALCAM/CD166 and
intracellular delivery of effector moieties.
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generally occurs in cells undergoing proliferation, and that it
acts both in the formation of neuromuscular contacts during
development and in guiding non-radial cell migration during
brain development (Fournier-Thibault et al., 1999; Heffron and
Golden, 2000) (reviewed by Swart, 2002). ALCAM/CD166 is
also present in a number of carcinoma cells and cell lines, and
in the invasive cells of melanocytic skin lesions where its
expression correlates with tumor progression (Degen et al.,
1998; van Kempen et al., 2000; Tomita et al., 2000; Swart,
2002; Kristiansen et al., 2003). On the other hand,
overexpression of a truncated ALCAM form in melanoma
cells, which is unable to support homotypic cell clustering,
relieves the constraints for tumor cell migration and apparently
promotes tissue invasion (van Kempen et al., 2001).
Collectively these reports support the hypothesis that
expression of ALCAM/CD166 introduces a more general
switch in cell programs, controlling the transition between cell
clustering and cell movement.
Several lines of evidence indicate that some members of the
cell adhesion molecule (CAM) family are not simply stable
residents on the cell surface. Instead, CAMs can be
dynamically regulated by various mechanisms, such as lateral
oligomerization, endocytosis and recycling to the cell surface,
proteolytic ectodomain shedding and transcriptional regulation
of expression (Kamiguchi and Lemmon, 2000a). ALCAM/
CD166 lateral oligomerization and ectodomain shedding have
been recently described (van Kempen et al., 2001; van Kempen
et al., 2004), although little is known about ALCAM/CD166
endocytosis besides a previous description of its ‘modulation’
(Pesando et al., 1986).
Our present finding that phages displaying anti-ALCAM/
CD166 specificity could be selected from an internalized phage
pool, suggests that ALCAM/CD166 is also capable of ligand-
induced internalization. We demonstrate that ALCAM/CD166
functional dynamics include ligand-induced endocytosis and
recycling to the cell surface. The endocytic pathway is clathrin-
dependent, but the internalization kinetics are slower than those
of transferrin. Finally, we show that such an endocytic pathway
allows the efficient delivery of an anti-ALCAM/CD166 scFv-
saporin immunotoxin into tumor cells, suggesting that this
scFv could be of use for the targeted delivery of effector
moieties into ALCAM/CD166-positive cells.
Materials and Methods
Cells, antibodies and reagents
The human cell lines IGROV-I and A2774 (ovarian carcinoma, from
J. Bénard, Institute Gustave Roussy, Villejuif, France), N592 and
GLC-4 [small cell lung cancer (SCLC), from J. Minna (National
Cancer Institute, Bethesda, MD), and from E. De Vries and L. De Leij
(Utrecht, The Netherlands) respectively], SK-N-BE and GI-ME-N
(neuroblastoma, from S. Carrel, Lausanne, Switzerland, and from the
Laboratory of Oncology, Istituto G. Gaslini, Genova, Italy,
respectively) were grown in RPMI 1640 (Sigma, St Louis, MO),
supplemented with L-glutamine, 10% heat inactivated FCS
(BioChrome KG, Berlin, Germany), and antibiotics at 37°C in a 5%
CO2 incubator. Culture medium for the murine cell lines L929
(connective tissue; ECACC, Salisbury, UK), F1F (fibrosarcoma; from
M. P. Colombo, Istituto Nazionale Tumori, Milano), Neuro2a
(neuroblastoma; ATCC, Rockville, MD), and for the COS-7 monkey
kidney cell line (ATCC) was DMEM (Sigma) with supplements and
culture conditions as above. T lymphoblasts were derived as described
(Renard et al., 2002). Monoclonal anti-ALCAM/CD166 antibodies
J4-81 and 3A6 were purchased from Antigenix America (New York,
NY) and BD Pharmingen (Becton Dickinson, San Diego, CA),
respectively. FITC-labeled anti-clathrin and anti-caveolin (IgM, clone
C060) antibodies were from BD Pharmingen. Anti-FLAG (clone M2)
antibody was from Sigma. Recombinant soluble human ALCAM/Fc,
murine ALCAM/Fc and human CD6/Fc chimeras were purchased
from R&D Systems (Minneapolis, MN). The anti-NIP scFv (Nissim
et al., 1994), a kind gift from G. Winter (MRC, Cambridge UK), was
modified by adding the FLAG-tag sequence and used as a control. The
anti-saporin monoclonal antibody (mAb) CY12.14 has been
previously described (Tazzari et al., 1993).
Selection of internalizing scFv by phage display
The non-immune scFv phage antibody library ETH-2 (Pini et al.,
1998), kindly provided by D. Neri, ETH Zürich and Philogen/
Philotec, Siena, Italy, and L. Zardi, Istituto G. Gaslini, Genova, Italy,
was selected by panning on IGROV-I human ovary carcinoma cells
following a modification of a protocol described (Poul et al., 2000).
Briefly, 5106 subconfluent adherent IGROV-I cells were incubated
for 1.5 hours rocking at 4°C, with 11011 colony forming units of
ETH-2 library, in the presence of 25106 human red blood cells, to
reduce non-specific binding. The cells were then extensively washed
with PBS and incubated with pre-warmed medium at 37°C for 15
minutes to allow endocytosis of surface-bound phage. To remove
phage bound to the extracellular matrix or to the culture plate,
adherent cells were trypsinized for 10 minutes at 37°C and washed
with culture medium at 4°C. Subsequently, to remove phage bound to
the cell surface, the cells were stripped three times with low pH
glycine buffer (150 mM NaCl, 100 mM glycine pH 2.5). Internalized
phages were recovered from within the cells by lysing with 100 mM
triethylamine for 4 minutes at 4°C, and neutralizing with 0.5 M Tris-
HCl pH 7.4. The cell lysate was used to infect TG1 Escherichia coli
to prepare phage for the next round of selection. A total of five rounds
of selection were performed. To obtain soluble scFv, phages recovered
from the fifth panning were used to infect HB2151 E. coli. Antibodies
binding IGROV-I cells were identified by cell ELISA (Poul et al.,
2000) using native soluble scFv expressed from randomly picked
single colonies. Cell-bound scFv was detected via its FLAG-tag using
the anti-FLAG M2 mAb (Sigma) followed by a HRP-conjugated goat
anti-mouse antibody (Caltag Laboratories, Burlingame, CA). The
diversity of positive clones was analyzed by PCR amplification and
DNA fingerprinting the scFv gene with BstN1 as described (Marks et
al., 1991).
Immunoprecipitation and purification of antigen using I/F8 scFv
Single-chain Fv I/F8 was purified from the culture broth of HB2151
E. coli cells using a Sepharose Protein A column (Amersham
Biosciences, Uppsala, Sweden), eluted with low pH, 100 mM glycine
and dialyzed against PBS for cell culture applications, as described
(Viti et al., 2000).
The I/F8 antigen was characterized by immunoprecipitation using
scFv antibodies bound to CNBr-activated Sepharose 4B according to
the manufacturer’s instructions (Amersham Biosciences). If required,
cell surface proteins were labeled with Sulfo-NHS-LC-biotin (Pierce,
Rockford, IL) as described for cells growing in suspension (De Rossi
et al., 1993) and for adherent cells (Le Bivic et al., 1989). Cells were
lysed with lysis buffer: 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150
mM NaCl, 1% Brij97 (Sigma), protease inhibitors (Complete C Mini,
Roche Diagnostics, Mannheim, Germany), and nuclei were discarded
after centrifugation at 400 g. After one pre-clearing cycle with anti-
NIP apten scFv coupled to Sepharose beads, specific absorption was
performed by incubating cell extracts with I/F8-Sepharose beads,
rotating for 3 hours at 4°C. Sepharose was then thoroughly washed
with lysis buffer, and bound material was eluted in SDS-PAGE sample
buffer. Immunoprecipitated proteins were fractionated by SDS-
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electrophoresis on 10% polyacrylamide gels under reducing and
non-reducing conditions. Biotin-labeled proteins were analyzed
by western blotting with HRP-conjugated streptavidin
(DakoCytomation, Carpinteria, CA), according to standard procedures.
Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-
TOF) peptide mass fingerprinting was performed on the silver-stained
protein excised from a preparative SDS-PAGE, as described
(Shevchenko et al., 1996). Analysis of tryptic fragments was
performed on a Voyager-DE STR time-of-flight instrument (Applied
Biosystems, Framingham, MA), equipped with a nitrogen laser
operating at 337 nm. Mass spectra of tryptic peptides were acquired
operating in the positive ion, delayed extraction and reflectron modes
using α-cyano-4-hydroxycinnamic acid (saturated solution in 50%
acetonitrile with 0.1% trifluoroacetic acid) as the UV-absorbing
matrix. Experimental conditions were as follows: accelerating voltage,
20,000 V; grid voltage, 94%; guide wire voltage, 0.050%; delay, 100
ns; laser power, 2487. Spectra were obtained by combining 400 scans,
applying mass calibration, baseline correction, noise filtering and de-
isotoping procedures using the spectrometer software (Data Explorer
version 4.0, Applied Biosystems). Monoisotopic peptide masses
were submitted to ProFound (http://129.85.19.192/profound_bin/
WebProFound.exe) and Mascot (http://www.matrixscience.com/) for
comparison with entries in the National Center for Biotechnology
Information (NCBI) sequence database.
Binding and internalization of ALCAM/CD166 antibodies and
ligands
Immunofluorescence was performed incubating 105 viable cells with
2 µg/ml scFv I/F8 plus 2 µg/ml anti-FLAG mAb, or with 2 µg/ml
anti-ALCAM/CD166 mAbs for 40 minutes on ice. Recombinant
soluble ALCAM/CD166 ligands CD6/Fc and ALCAM/Fc chimeras
were used at 1 µg/ml and 10 µg/ml, respectively. As secondary
reagents, FITC-conjugated goat anti-mouse Ig and anti-human Ig
(Caltag Laboratories) were used. The competition between
ALCAM/CD166 antibodies and ligands CD6/Fc and ALCAM/Fc was
assessed by flow cytometry on SCLC N592 cells. Subsaturating
amounts of binder molecule were challenged with varying amounts
of I/F8 scFv in a 30-minute incubation on ice with 105 viable N592
cells. The cells were then washed twice with PBS 2% FCS and
incubated with the appropriate FITC-conjugated secondary antibody.
After washes, cells were analyzed on a FACScan (Becton Dickinson,
Mountain View, CA). The amount of binder molecules bound to the
cells was measured as mean fluorescence intensity (MFI).
To induce internalization, 2 µg/ml I/F8 scFv were allowed to bind
to tumor cells monolayers in the presence or in the absence of an equal
amount of anti-FLAG mAb, for 40 minutes on ice. When required,
25 µg/ml RITC- or FITC-labeled human transferrin (Molecular
Probes, Eugene, OR), or 5 µg/ml FITC-labeled cholera toxin B
(Sigma) were added. As a negative control, an anti-NIP apten scFv
was used. After scFv binding, cells were extensively washed with cold
PBS and then incubated at 37°C for the indicated times, to allow
internalization. Surface-bound scFv were stripped by three washes
with cold low pH glycine buffer, and cells were then fixed for 5
minutes on ice with 4% paraformaldehyde (PFA) in PBS pH 7.4 and
permeabilized with 0.5% Triton X-100 in PBS. Endocytosed scFv was
then detected by staining with anti-FLAG mAb, when required,
followed by fluorochrome-conjugated goat anti-mouse Ig. When
required, cell nuclei were counterstained with a 15-minute incubation
at 37°C with a 1 µg/ml propidium iodide (Sigma), 10 µg/ml RNase
A (Sigma) solution. The cells were mounted onto slides with Mowiol
and analyzed by confocal fluorescence microscopy. Alternatively, the
incubation with the primary antibody was followed by a 40-minute
incubation on ice with FITC- or RITC-labeled secondary antibody,
and the samples were then incubated at 37°C to allow internalization
of the immunocomplexes. Surface-bound scFv were stripped as
described above and the cells were fixed and analyzed. When the
colocalization with other molecules was investigated, after fixation the
samples were extensively washed with PBS and the secondary
antibody free valences were saturated by a 30-minute incubation with
mouse IgG. A second round of PFA fixation followed, and finally the
cells were incubated with FITC-labeled anti-clathrin, or with anti-
caveolin antibody. Anti-caveolin was detected with a RITC-labeled
goat anti-mouse IgM antibody. Isotype-matched negative controls
were included. Results were analyzed using an Olympus (Olympus
Optical, Tokyo, Japan) laser-scanning microscope FV500 equipped
with an Olympus IX81 inverted microscope and Argon ion 488 nm,
He-Ne 543 nm, and He-Ne 633 nm lasers. Digital images were
acquired through PLAPO 40 and 60 objectives, with the Fluoview
4.3b software program. Images were acquired sequentially as single
transcellular optical sections, archived in TIFF and mounted using
Photoshop.
Internalization and recycling
ALCAM/CD166 endocytosis and recycling was evaluated by its
protection from cleavage by a membrane impermeable reagent based
on published pulse-chase protocols (Fabbri et al., 1999; Garza and
Birnbaum, 2000), with minor modifications. Subconfluent cells plated
on 60 mm diameter dishes were washed twice in PBS and incubated
for 30 minutes on ice in the presence of 0.5 mg/ml NHS-SS-biotin
(Pierce) in PBS. Labeling reaction was then stopped by two PBS
washes, followed by a 10-minute incubation on ice in 150 mM NaCl
containing 10 mM glycine. Labelled cells were then allowed to react
with 5 µg/ml anti-ALCAM/CD166 3A6 mAb for 40 minutes on ice,
and subsequently were incubated at 37°C to allow internalization for
the indicated times. The samples were then returned to ice and treated
with three successive reductions of 15 minutes on ice with a reducing
solution containing 50 mM GSH, 1 mM MgCl2, 0.1 mM CaCl2, 0.2%
BSA, 75 mM NaOH and 75 mM NaCl, pH 8.6. Cells were washed
carefully in PBS and either lysed or chased by re-incubation at 37°C
for various times in duplicate samples. After the incubation, only one
of the two samples was again reduced to quantify the amount of
protein that recycled back to the plasma membrane. The samples were
then collected, lysed and the protein content of lysates was measured
by Micro BCA protein assay kit (Pierce). Equal amounts of proteins
were then processed for immunoprecipitation with I/F8-Sepharose as
described above.
Immunotoxin and toxicity test
Type 1 single-chain RIP saporin S6 and the I/F8 scFv were conjugated
via a disulfide bond between chemically inserted sulfhydryl groups.
The resulting I/F8/RIP conjugate was separated from the unreacted
reagents and from RIP homopolymers by affinity chromatography
with rProtein A-Sepharose (Amersham Biosciences). The
immunotoxin was then separated from the unconjugated scFv by gel
filtration on a Sephacryl S200 column as described (Tazzari et al.,
2001). After conjugation, the toxin:scFv molar ratio was 1.4 and the
immunotoxin inhibitory activity of protein synthesis, assayed in a
rabbit reticulocyte lysate system, showed an IC50 of 4.87 ng/ml. The
effects of the immunotoxin on cell lines were evaluated as inhibition
of protein synthesis and measured as [3H]leucine incorporation. Cells
(104/well) were seeded in 96-well microtiter plates and immunotoxin
was added to final concentrations ranging from 10–11 to 10–7 M, as
RIP. Parallel samples were run with RIP alone, I/F8 scFv alone, and
a mixture of unconjugated scFv and RIP. After incubation for 48
hours, 74 kBq L-[4,5-3H]leucine (Amersham Biosciences) per well
was added. Eighteen hours later, the cells were harvested with an
automatic cell harvester onto glass fiber paper, and the radioactivity
incorporated was measured with a liquid scintillation analyzer Tri-
Carb 2100TR (PerkinElmer, Boston, MA). Each experiment was













Immunotoxin entering into the cells was visualized by indirect
immunofluorescence. Briefly, 0.2 µg/ml I/F8/RIP or free RIP were
allowed to bind to tumor cells monolayers in the presence of the anti-
RIP mAb CY12.14 at 0.5 µg/ml, for 40 minutes on ice. The samples
were then incubated at 37°C to allow internalization of the
immunocomplexes, surface-bound toxins were stripped, and the cells
were fixed, permeabilized, stained with FITC-labeled secondary
antibody and analyzed as described above.
Results
Isolation and characterization of the I/F8 scFv anti-
ALCAM/CD166
The non-immune scFv phage antibody library ETH-2, was
selected for internalizing phage antibodies by panning on the
IGROV-I human ovary carcinoma cell line. Five rounds of
selection were performed. Selections were monitored, starting
from round 3, by titrating the number of phage bound to the
cell surface and recovered in the first glycine wash (wash 1,
required to remove phage bound to the cell surface) and the
number of endocytosed phage recovered from within the cell
(cell lysate). Data shown in Table 1 suggest that phage were
selected on the basis of endocytosis into IGROV-I cells. Thus,
the wash 1:input phage ratio increased by a factor of 10,
whereas the cell lysate:input phage ratio showed a 500-fold
increase. Screening by ELISA on cells, using native soluble
scFv expressed from randomly picked single colonies, showed
that 45 out of 96 clones (46.9%) bound IGROV-I cells, and
gave no signal above background on human long term cultured
T lymphoblasts. The cell-bound scFv were detected via their
FLAG-tag using an anti-FLAG monoclonal antibody. The
diversity of positive clones was analyzed by PCR amplification
and DNA fingerprinting of the scFv gene with BstN1 (Marks
et al., 1991). scFv were then grouped on the basis of their
digestion pattern. Further investigation of scFv specificity is
here limited to one representative clone: the I/F8 scFv. The
CDR3 nucleotide sequence insert of the I/F8 scFv DP47 heavy
chain is GGGTATGTGGCT and the one of the I/F8 scFv
DPL16 light chain is CCCCCTTTTAGTGCGGAG.
Immunofluorescence analysis on a panel of tumor lines,
showed that the I/F8 antigen is broadly distributed in human
tumors derived from various tissues, although with great
differences in the level of surface expression (not shown).
Immunoprecipitation from biotin surface-labeled IGROV-I
tumor cells, showed that the I/F8 antigen is a 116 kDa monomer
(Fig. 1A). Similar protein bands were detected in I/F8-
immunoprecipitated molecules from various human tumor cells
(Fig. 1B). The 116 kDa protein bands present in I/F8
immunoprecipitates from two IGROV-I cellular extract
preparations were subsequently subjected to in-gel digestion
with trypsin and protein identification with MALDI-TOF mass
spectrometry and peptide mass fingerprinting. A database search
revealed identity with ALCAM/CD166 or MEMD protein with
high Z-scores (2.31 and 2.41, respectively) and a good sequence
coverage (ProFound). The MEMD protein is identical to
ALCAM/CD166 (Degen et al., 1998). The immunoprecipitates
from the other cell lines, although displaying slightly different
molecular weights, were again identified as ALCAM/CD166.
The differences in molecular weight are probably due to tissue
specific variation in N-glycosylation pattern (Pourquié et al.,
1992; Denziger et al., 1999).
Comparative analysis of the I/F8 scFv and of the murine
monoclonal antibody J4-81 (specific for human ALCAM/
CD166) by immunofluorescence indicated that the two reagents
display an identical pattern of reactivity on a panel of human
Journal of Cell Science 118 (7)
Table 1. Phage antibody library selection on IGROV-I cells
indicates the enrichment of internalizing phages
Output/
Phage output input ratios (10–3)
Round Phage input Wash 1 Cell lysate Wash 1 Cell lysate
3 2.4109 2.0107 7.5105 8.3 0.3
4 3.3109 1.2108 0.9108 36.3 27.2
5 8.0108 7.0107 1.5108 87.5 187.5
Fig. 1. Characterization of the I/F8 antigen. (A) Immunoprecipitation
from Sulfo-NHS-LC-biotin surface-labeled IGROV-I tumor cells
using the I/F8 scFv coupled to CNBr-activated Sepharose beads.
Immunoprecipitates were resolved by SDS-PAGE on a 10%
polyacrylamide gel, and revealed by western blot analysis using
HRP-conjugated Streptavidin and chemiluminescence. The I/F8
antigen is a 116 kDa monomer under both reducing (ME+) and non-
reducing (ME–) conditions. Immunoprecipitates using an irrelevant
scFv coupled to Sepharose beads were run as negative controls (ctr).
(B) Silver-stained preparative immunoprecipitation and SDS-PAGE
analysis of the I/F8 antigen. I/F8 immunoprecipitates from several
tumor cell lines were resolved by SDS-PAGE on a 10%
polyacrylamide gel under reducing conditions, and revealed by
staining with silver nitrate. Bands were then excised from the gel and
processed for MALDI-TOF analysis. (C) Immunofluorescence
analysis of I/F8 (black line) and J4-81 (gray line) reactivity on
various human and murine tumor cell lines. Broken line represents
negative control with an irrelevant scFv. (D) Silver staining of I/F8
immunoprecipitated molecules from three murine tumor cell lines,
resolved by SDS-PAGE on a 10% polyacrylamide gel. Numbers on
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tumor cell lines (Fig. 1C). In addition, mouse F1F fibrosarcoma
cells and L929 connective tissue cells (Fig. 1C) and monkey
COS-7 kidney cells also showed reactivity with I/F8, indicating
that the I/F8 scFv recognizes a phylogenetically conserved
epitope, whereas the J4-81 antibody does not react with murine
cells (Fig. 1C). Consistent with the immunofluorescence data,
a 110 kDa protein was immunoprecipitated by I/F8 also from
murine cells (Fig. 1D). The anti-ALCAM/CD166 specificity of
the I/F8 scFv was further confirmed by ELISA on both
recombinant soluble human ALCAM/Fc and murine ALCAM/
Fc chimeras (not shown). ELISA on the recombinant soluble
human ALCAM/Fc chimera also showed that 42 of the 45 scFv
selected on the base of their reactivity with IGROV-I cells were
ALCAM/CD166-specific. The three clones whose scFv did not
recognize ALCAM/Fc showed indeed BstN1 digestion patterns
different from the DNA fingerprint of the I/F8 scFv gene and
from each other. Their antigen specificity is currently under
investigation.
The ALCAM/CD166 epitope recognized by I/F8 was partly
characterized by cell surface binding interference experiments
with both ALCAM/CD166 ligands, measured by flow
cytometry on the SCLC N592 cell line, that grows in
suspension and is more suitable for this type of analysis. I/F8
scFv competed with both CD6/Fc and ALCAM/Fc binding to
the cell surface (Fig. 2). The J4-81 antibody inhibited only the
CD6/Fc binding (not shown), as expected (van Kempen et al.,
2001). These data suggest that the I/F8 epitope is located in the
V1 domain, which is involved in ligand binding (van Kempen
et al., 2001). The difference between the ALCAM/Fc and the
CD6/Fc concentration in the binding/competition assay
(tenfold difference) reflects the difference in affinity between
the homophilic and the heterophilic interactions recently
reported (Hassan et al., 2004).
In addition, I/F8 failed to compete with both J4-81 and 3A6
antibodies for the binding to ALCAM/CD166 expressed on the
surface of N592 cells (Table 2), indicating that the I/F8 scFv
recognizes a different epitope.
ALCAM/CD166 is endocytosed slowly via a clathrin-
dependent pathway
As the I/F8 phage antibody was selected on the basis of
endocytosis into IGROV-I cells, we first investigated by
confocal immunofluorescence microscopy whether the
ALCAM/CD166 molecule could be internalized upon ligand
binding. Live IGROV-I cell monolayers were allowed to bind
I/F8 scFv at 4°C in the presence or absence of the anti-FLAG
mAb as dimerizing agent. Cells were then moved to 37°C for
the indicated times to induce internalization and were
subsequently acid-washed to strip the surface-bound
molecules. As control of the efficiency of surface stripping by
acid washing, one sample was acid-treated directly after
incubation at 4°C. Samples were then fixed, stained with
labeled secondary antibodies and visualized by confocal
microscopy. The residual staining detected in the stripped
samples therefore corresponded to the endocytosed molecules.
At 4°C the cells bind the antibody (Fig. 3A) but do not
internalize, as surface-stripping completely removes the signal
(Fig. 3B). On the other hand, upon I/F8 scFv binding
ALCAM/CD166 was endocytosed after a 30-minute
incubation at 37°C (Fig. 3C), and dimerization by anti-FLAG
mAb appeared to substantially increase the internalization
process (Fig. 3D). ALCAM/CD166 internalization was also
induced by the ALCAM/CD166 soluble ligand CD6/Fc
chimera, and by the murine anti-ALCAM/CD166 mAbs 3A6
and J4-81 (not shown).
The kinetics of ligand-induced ALCAM/CD166 endocytosis
were then investigated and compared with that of transferrin,
a well-established marker of the endosomal pathway, by
triggering I/F8-induced internalization in the presence of
transferrin-FITC. ALCAM/CD166 is internalized in a time-
dependent manner at long time intervals (Fig. 4). After
incubation at 4°C, I/F8 staining was associated with the cell
surface and was completely removed by stringent acid washes
(Fig. 4A, a). After 10 minutes at 37°C, I/F8 staining was still
associated primarily with the cell surface, as it was efficiently
stripped, but it assumed a ‘punctate’ pattern (Fig. 4A, c). After
30 minutes a more vesicular pattern was observed close to the
cell surface and acid wash-resistant staining appeared,
indicating presence of internalized molecules (Fig. 4A, e). At
60 minutes, the intracellular vesicular staining was more
Table 2. I/F8 scFv does not compete with either J4-81 or
3A6 binding to ALCAM/CD166 expressed on the surface
of SCLC N592 cells
Mean fluorescence intensity
Competitor nM J4-81 (3 nM) 3A6 (3 nM)
PBS - 40 38
I/F8 scFv 3 37 41
I/F8 scFv 30 45 47
I/F8 scFv 300 44 59
I/F8 scFv 600 54 63
NIP scFv 600 38 38
Fig. 2. Cell surface binding interference experiments between
ALCAM/CD166 ligands and the I/F8 scFv, measured by flow
cytometry on N592 SCLC cells. Ligand binding in the presence of
I/F8 is indicated by black triangles and binding in the presence of the
irrelevant anti-NIP scFv is indicated by empty triangles. CD6/Fc and












pronounced (Fig. 4A, g), but the label formed small ‘spots’
that, unlike the transferrin signal, distributed in the
submembrane region and did not cluster toward the perinuclear
area (Fig. 4B). As the kinetics of ALCAM/CD166 endocytosis
seems much slower than that of transferrin (Fig. 4A, b,d,f,h),
the little colocalization between the two signals could be
attributed to asynchrony of the internalization process.
Alternatively, the two molecules could follow different
endocytic pathways. To address this issue, the ALCAM/CD166
internalization route was studied by sequential
immunofluorescence using both the I/F8 scFv and the J4-81
mAb, and anti-clathrin or anti-caveolin-1 antibodies on A2774
cells, which display high caveolin-1 expression. Internalized
ALCAM/CD166 colocalized primarily with clathrin (Fig.
5A,B) and not with caveolin-1 (Fig. 5D,E), showing that it is
indeed routed to early endosomes via clathrin-coated pits. As
positive controls, molecules colocalizing with clathrin and
caveolin-1, such as, respectively, transferrin and cholera toxin
B, were investigated (Fig. 5C,F).
Endocytosis may dynamically control the amount of cell
surface expressed molecules under certain physiological
conditions (Minana et al., 2001; Kamiguchi and Lemmon,
2000b). We then examined the internalization of ALCAM/
CD166 in cells undergoing division. In A2774 human ovary
carcinoma cells the ligand-triggered internalization of the
ALCAM/CD166 molecule is maximal at the cleavage furrow
during cytokinesis (Fig. 6B,C), suggesting that ALCAM/CD166
internalization may play a role in the rearrangement of cell-cell
contacts. This phenomenon was frequently observed in low-
density cell cultures, where 55±5% of cell doublets appeared as
in Fig. 6 in two different experiments.
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Fig. 3. I/F8-induced internalization of the ALCAM/CD166 molecule.
IGROV-I cells were incubated with I/F8 scFv at 4°C in the presence
(A,B,D) or in the absence (C) of the anti-FLAG-tag mAb as
dimerizing agent. Cells were then placed on ice (A,B) or moved to
37°C for 30 minutes to induce internalization (C,D), and were
subsequently untreated (A) or acid-washed to strip the surface-bound
molecules (B-D). Samples were then fixed, permeabilized, stained
with FITC-labeled secondary antibodies and visualized by using an
Olympus confocal laser microscope system. Insets show staining
with the irrelevant anti-NIP scFv as a negative control, except B
where the Propidium Iodide-counterstained nuclei present in the
same field are visualized. The residual staining detected in the
stripped samples therefore corresponds to the endocytosed
molecules. Magnification, 400.
Fig. 4. Internalization kinetics of ALCAM/CD166 compared to
transferrin. (A) ALCAM/CD166 internalization is time dependent
and slower than transferrin. Confocal microscopic imaging of
IGROV-I cells incubated with I/F8 scFv and anti-FLAG mAb in the
presence of transferrin-FITC. The samples were allowed to
internalize for the indicated times (in minutes) before acid-stripping
of the surface-bound molecules, fixing, permeabilizing and staining
with RITC-labeled secondary antibody. Images were acquired
sequentially as single transcellular optical sections, and the same
section is shown stained with I/F8 (left panels) and with transferrin
(right panels). Insets show the non-stripped samples. (B) Internalized
ALCAM/CD166 distributes in the sub-membrane region and does
not cluster toward the perinuclear area. Confocal microscopic
imaging of IGROV-I cells stained with I/F8 plus anti-FLAG mAb,
allowed to internalize for 60 minutes, acid-washed to strip the
surface if required (right panel), fixed, permeabilized and stained
with FITC-labeled secondary antibody. Nuclei were counterstained
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Internalized ALCAM/CD166 recycles to the plasma
membrane
The ability of ALCAM/CD166 to internalize and recycle from
the endocytotic compartment back to the cell surface was then
biochemically analyzed. Cells were labeled with NHS-SS-
biotin on ice, incubated with the anti-ALCAM/CD166 murine
mAb 3A6 for various times at 4°C as controls or at 37°C to
allow internalization, and then exposed to the membrane
impermeable reducing agent glutathione (GSH). The
endocytosed pool of proteins was thus protected from
reduction and remained biotinylated. The cell samples were
then either lysed and immunoprecipitated, or chased at 37°C
for various time periods. At each time point, cells were re-
exposed to GSH to remove biotin from proteins that
had recycled back to the cell surface, lysed and
immunoprecipitated. Equal amounts of proteins from cell
lysates were subjected to immunoprecipitation using the I/F8
scFv coupled to sepharose, whose binding to ALCAM/CD166
molecules is not blocked by the 3A6 mAb. The antibody-
induced internalization of ALCAM protein was detected (Fig.
7A) and showed a time-dependent increase, with a maximum
at 40 minutes of incubation (Fig. 7B). Such slow kinetics are
consistent with the fluorescence microscopy data (Fig. 4).
Chase experiments showed that internalized ALCAM/CD166
molecules could recycle back to the cell surface. The pool of
biotinylated ALCAM/CD166 was indeed decreased after a 20-
minute chase (Fig. 7C) and was almost undetectable after a 30-
minute chase (Fig. 7D). These data indicate that internalized
ALCAM/CD166 molecules are not all directed to the
degradative pathway but can be recycled to the cell surface,
where they become susceptible to the reducing effect of GSH.
We can therefore conclude that surface oligomerization of
ALCAM/CD166 molecules triggers an endocytosis and
recycling process that proceeds at a slow rate.
The ALCAM/CD166 internalization pathway is suitable
for intracellular drug delivery
Ribosome-inactivating proteins (RIPs) are N-glycosylases
from plants that cleave one or more adenine molecules from
ribosomal RNA, thus damaging ribosomes in an irreversible
manner. Thus the cytotoxicity of RIPs strictly depends on their
entrance into the cell. We then evaluated the potential of the
scFv I/F8 as an RIP carrier by producing an immunotoxin
formed by I/F8 linked to the type 1 RIP saporin via an artificial
disulfide bond. The activity of the I/F8/RIP immunotoxin was
assayed on both human and murine ALCAM/CD166-positive
and -negative cell lines by a protein synthesis inhibition assay.
As shown in Table 3, different ALCAM/CD166-positive cells
showed different sensitivity to free saporin or to the I/F8/RIP
conjugate, but the toxicity of the immunotoxin was always at
least a 100-fold higher than that of the free RIP. For example,
the I/F8/RIP had an IC50 of 3.1910–9 M with saporin on the
Fig. 5. Internalized ALCAM/CD166 colocalizes primarily with
clathrin. A2774 cells were stained either with I/F8 scFv plus anti-
FLAG mAb (A,D) or with J4-81 mAb (B,E), allowed to internalize
for 40 minutes at 37°C, acid-washed to remove the surface-bound
antibody, fixed, permeabilized and stained with fluorochrome-labeled
secondary antibody. As the colocalization with other molecules was
investigated, the secondary antibody free valences were saturated by
a 30-minute incubation with mouse IgG, followed by a second round
of PFA fixation, and finally the cells were incubated with FITC-
labeled anti-clathrin or with anti-caveolin antibodies. Anti-caveolin
was then detected with RITC-labeled goat anti-mouse IgM antibody.
As colocalizing positive controls, transferrin-RITC (TF, panel C) and
cholera toxin B-FITC (CT B, panel F) were allowed to internalize for
10 and 40 minutes, respectively, at 37°C. Cells were then acid-
washed, fixed, permeabilized and processed for staining with anti-
clathrin and anti-caveolin antibodies. Double immunofluorescence
was visualized by confocal microscopy. Single-color
immunofluorescence images are shown in the small panels and the
corresponding merged images are shown in the large panels. Original
magnification, 600.
Fig. 6. Ligand-triggered internalization of the ALCAM/CD166
molecule is maximal at the dividing cell contact region. Confocal
microscopic imaging of A2774 cells stained with I/F8 plus anti-
FLAG mAb, kept on ice (A,D) or allowed to internalize for 40
minutes (B,C), acid-washed to strip the surface if required (B,C,D),
fixed, permeabilized and stained with FITC-labeled secondary













L929 murine cell line, whereas free saporin mixed with scFv
was toxic only at 3.2210–7 M concentration. Surface
ALCAM/CD166 negative cells, as the murine Neuro2a
neuroblastoma line, were not affected.
The kinetics of I/F8/RIP entering into the cell could also be
visualized (Fig. 8). Live A2774 cell monolayers were allowed
to bind either the I/F8/RIP immunotoxin or RIP alone at 4°C
in the presence of the anti-RIP mAb CY12.14. Cells were then
kept on ice as a control or at 37°C for the indicated times to
induce internalization and were subsequently acid-washed to
strip the surface-bound molecules. Samples were then fixed,
permeabilized, stained with FITC-labeled secondary antibody,
counterstained with Propidium Iodide and visualized by
confocal microscopy. The staining detected in the stripped
samples therefore corresponded to the endocytosed molecules.
At 4°C the cells bind but do not internalize the immunotoxin,
as surface stripping completely removes the signal (Fig. 8A,B),
whereas at 37°C they internalize it in a time-dependent manner
at longer time intervals (Fig. 8C-E). Altogether, these data
demonstrate that the I/F8 scFv can deliver moieties inside the
cell through ALCAM/CD166 internalization. 
Discussion
In this study we describe the selection and characterization of
a human anti-ALCAM/CD166 scFv, its use in the study of the
internalization and recycling of cell surface ALCAM/CD166,
and its potential use for the immunotargeting of therapeutics
into ALCAM/CD166-positive cells.
The I/F8 scFv was isolated from a large non-immune phage
antibody library. Most of the antibodies isolated from such
combinatorial libraries expressed on phage have been selected
using immobilized purified antigens or peptides, facing the risk
that the selected antibodies do not recognize the native protein
in its physiological context. On the other hand, attempts to
select non-immune libraries on native antigens expressed on
living cells have been successful in only a few cases (Marks et
al., 1993; de Kruif et al., 1995; Vaughan et al., 1996; Wong et
al., 2001). The limiting factor in the selection by cell panning
is related to the high background binding of non specific
phages compared to the relatively low binding of phages
specific for a given antigen (Pereira et al., 1997; Watters et al.,
1997; Becerril et al., 1999). Here we show the advantage of
selecting for antibodies that trigger a biological function, such
as receptor-mediated endocytosis, to reduce the high
background binding when selecting phage antibodies by
panning on living cells. In addition, this approach may allow
the selection of antibodies capable of mimicking natural ligand
functions, a property that may have practical applications. In
the case of I/F8, the capacity of being endocytosed as a phage-
displayed scFv was retained by the monomeric soluble scFv,
albeit with a limited efficiency when compared with its
dimerized form. However, the internalizing properties of the
scFv monomer were sufficient for the intracellular delivery of
a drug that requires entry into the cell for its activity (Stirpe,
2004).
Endocytosis is involved in several cellular processes
including regulation of cell-surface expression of signaling
molecules, and proceeds through a variety of clathrin-
dependent and clathrin-independent endocytic pathways. Our
present data suggest that ALCAM/CD166 can be internalized
following soluble ligand engagement primarily through a
clathrin-dependent pathway. Similarly clathrin-dependent
internalization has been reported for other members of the
CAMs family, such as N-CAM (Minana et al., 2001) and L1
molecules (Kamiguchi et al., 1998). However, kinetic studies
revealed that ALCAM/CD166 internalization proceeds at
a slower rate than that of other well known examples of
clathrin-mediated endocytosis, such as the transferrin. Slow
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Table 3. Inhibitory effect of immunotoxin and a mixture of
free saporin and I/F8 on protein synthesis by target cell
lines
IC50 (nM)*






*Results are representative of two different experiments per cell line, each
performed in triplicate.
Fig. 7. Ligand-induced internalization and recycling of
ALCAM/CD166 molecules. (A) A2774 cells were surface-labeled
with NHS-SS-biotin, incubated for 30 minutes at 37°C with or
without the anti-ALCAM/CD166 mAb 3A6, treated with the
reducing agent GSH, lysed and immunoprecipitated with I/F8 scFv
coupled to Sepharose beads. Residual biotin-labeled molecules
identify internalized proteins. (B) The kinetics of 3A6 mAb-triggered
ALCAM/CD166 internalization was evaluated at different time
points prior to GSH treatment and lysis. Optimal receptor
internalization is at 40 minutes. The efficiency of surface NHS-SS-
biotin stripping by GSH was evaluated at different time points on
3A6-treated cells maintained at 4°C. (C) To analyze receptor
recycling, biotin-labeled and 3A6-treated A2774 cells were allowed
to internalize ALCAM/CD166 for 40 minutes and were treated with
GSH. Cells were then re-incubated at 37°C for 20 minutes to chase
internalized receptors, and treated with (+) or without (–) the
reducing agent to remove the label from molecules re-expressed to
the cell surface. Cell lysis and I/F8-sepharose bead
immunoprecipitation followed. Internalized ALCAM/CD166
recycles to the cell surface. (D) Kinetics of recycling. NHS-SS-
biotin-labeled internalized receptors were chased by re-incubation at
37°C for different time points (t) before the second GSH treatment
and immunoprecipitation. Immunoprecipitates were resolved by
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internalization kinetics have also been described also for other
receptors internalized through clathrin-dependent pathways
(Innamorati et al., 2001; Bronfman et al., 2003). In addition,
unlike transferrin, internalized ALCAM/CD166 molecules
appeared to localize predominantly in a sub-membrane
compartment even at later time points.
In the well-known clathrin-dependent endocytic pathway,
internalized molecules are delivered to the early endosome and
then trafficked either to the recycling endosome or to the late
endosome-lysosome pathway (reviewed by Mellman, 1996;
Sorkin and von Zastrow, 2002). As the internalized ALCAM/
CD166 molecule seemed to reside in the sub-membrane
region, we investigated whether it could recycle back to the cell
surface. A biochemical assay based on NHS-SS-biotin labeling
of surface molecules and treatment with a non-cell-permeable
reducing agent (GSH) able to cleave the SS-biotin link, allowed
us to demonstrate that ALCAM/CD166 is indeed endocytosed
and recycled back to the cell membrane within 30 minutes of
chasing with GSH.
Several lines of evidence indicate that CAMs do not simply
act as an inert glue that mediates static cell-cell interactions but
their surface expression and adhesivity is dynamically
controlled to respond to different environmental requirements.
For example, cell adhesion can be spatially regulated by the
polarized internalization and recycling of CAMs (reviewed by
Murase and Schuman, 1999; Kamiguchi and Lemmon, 2000a;
Kamiguchi, 2003). As cytoskeletal constraints are known to
regulate ALCAM/CD166 lateral mobility (Nelissen et al.,
2000), and during cytokinesis actin filaments are dynamically
reconstructed and concentrated to the cleavage furrow
(Straight and Field, 2000), we investigated ALCAM/CD166
internalization in epithelial cells undergoing cytokinesis. Our
present data indicate that ligand-induced ALCAM/CD166
internalization does indeed appear concentrated at the cleavage
furrow, where cell-cell contacts must be modified. This
observation suggests that ALCAM/CD166 internalization,
which requires ligand binding, is also dependent on
cytoskeleton dynamics.
In addition to the ability to trigger ALCAM/CD166
internalization, which is shared with other soluble ligands, two
remarkable features characterize the I/F8 scFv: the reactivity
across different species (human, mouse, monkey) and the
efficient competition with soluble ligand binding, both CD6/Fc
and ALCAM/Fc chimeras. It is well known that phage display
libraries potentially lead to a different spectrum of epitopes
from natural immune systems, also generating reagents against
the conserved and non-immunodominant regions of a given
antigen (Nissim et al., 1994), as is for the case for the I/F8 scFv.
A previous targeted mutagenesis study mapped the protein
surface structure involved in heterophilic interaction in the N-
terminal Ig (V1) domain of the ALCAM/CD166 molecule
(Skonier et al., 1996). The homophilic interaction site was also
located in the same V1 domain by protein truncation
experiments (van Kempen et al., 2001). The finding that the
I/F8 scFv can efficiently compete with binding of both soluble
ALCAM/Fc and CD6/Fc chimeras, strongly suggests that the
I/F8 epitope also maps to the V1 domain of the ALCAM/
CD166 molecule.
The CD6 binding site in ALCAM/CD166 is highly
conserved in different homologs and mediates cross-species
heterophilic binding, whereas the β-sheet face, opposite the
CD6 binding site, is less conserved. This observation provided
a molecular rationale for the apparent inability to obtain
murine monoclonal antibodies against the CD6 binding site
(Skonier et al., 1996; Bowen et al., 1997). Only the J4-81
murine antibody blocked heterophilic ALCAM/CD166-CD6
interactions (Bowen et al., 1996), but its reactivity was limited
to human ALCAM/CD166. As the I/F8 scFv is reactive across
different species, and blocks soluble ALCAM/CD166 ligands
binding, we hypothesize that its epitope is mapped within the
conserved CD6-binding protein surface. Several studies
involved the ALCAM/CD166 molecule in the process of cell
spreading, and in particular in the metastatic behavior of
different tumors, such as human melanoma (van Kempen et al.,
2000) or murine fibrosarcoma (Choi et al., 2000). Thus the
availability of a reagent such as I/F8, which is capable of
blocking ALCAM/CD166 functions, may provide a useful tool
to interfere in ALCAM functions and analyze its functional
role in the metastatic process.
The fully human origin of the I/F8 scFv, together with the
demonstration that it can be used for the delivery of drugs into
a cell, suggests potential applications in tumor targeting.
However, the expression of the ALCAM/CD166 molecule on
several normal tissues (Uchida et al., 1997; Cortés et al., 1999;
Swart, 2002) may hamper the systemic delivery of I/F8
conjugated to highly toxic molecules. Nonetheless, the
possible use of I/F8 conjugates in local tumor therapy, or for
targeting of less toxic compounds to ALCAM/CD166-positive
Fig. 8. Internalization kinetics of the I/F8/RIP immunotoxin. A2774
cells were incubated with either I/F8/RIP (large and small left-hand
panels) or RIP alone (small right-hand panels) at 4°C in the presence
of the anti-RIP mAb CY12.14 as dimerizing agent. Cells were then
left on ice (A,B) or transferred to 37°C for different times to induce
internalization (C,D,E), and were subsequently untreated (small
panels) or acid-washed to strip the surface-bound molecules (large
panels). Samples were then fixed, permeabilized, stained by FITC-
labeled secondary antibody and nuclei were counterstained with
Propidium Iodide. Samples were visualized by using an Olympus
confocal laser microscope system. Crosslinking the immunotoxin
with anti-RIP mAb allowed the visualization of the internalized
fraction at concentrations as low as 110–8 M I/F8/RIP (about 0.2
µg/ml). This amount of immunotoxin was used, as it is the highest
concentration that still shows a 100-fold difference in toxicity when












cells, may represent an attractive possibility. The recycling
experiments show that not all the ALCAM/CD166 molecules
are involved in the internalization process, but that a relevant
amount of ALCAM/CD166 is still available at the cell surface.
These molecules may indeed represent a suitable target for the
delivery of other biological modifiers such as immune-
stimulating agents. 
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